AAN 2022 | Current imaging techniques in predicting MS outcomes

Dejan Jakimovski, MD, PhD, Buffalo Neuroimaging Analysis Center, Buffalo, NY, comments on recent advances in imaging methods for predicting disease outcomes in multiple sclerosis (MS). PET-based imaging and the use of radiotracers such as [18F]PBR06 have enabled the monitoring of microglial activity as well as drug efficacy in the body. These techniques have demonstrated these medications can halt relapse in patients but further research is required to elucidate biomarkers for secondary progression. Leptomeningeal contrast enhancement may be able to track continuous inflammation in patients. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.